NCT07061210View on ClinicalTrials.gov

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

January 1, 2027

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

HRS-2189

HRS-2189

DRUG

Adebrelimab

Adebrelimab

DRUG

BP102

BP102

All Listed Sponsors
lead

Fudan University

OTHER